[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:urothelial-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":310,"states":332},"Urothelial Carcinoma",118,105,[8,16,23,30,36,43,49,55,61,67,73,79,86,92,98,104,110,116,122,128,134,140,146,152,158,164,170,176,182,188,194,199,205,211,217,223,228,234,240,246,252,258,264,270,276,281,286,292,298,304],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06524544","A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer",[12],"Phase 3","RECRUITING","2026-08-26T02:16:48.735701Z","2026-07-24T01:27:14.888700Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06434350","Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:16:49.565137Z","2026-07-05T05:32:16.753286Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07087860","Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers",[27],"Phase 2","2026-08-26T02:17:52.450442Z","2026-07-05T05:32:16.732547Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07419295","A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)",[12],"2026-08-26T02:15:09.079045Z","2026-07-05T05:32:16.680397Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT07129993","Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma",[40],"Phase 2\u002FPhase 3","2026-08-26T02:19:11.399072Z","2026-06-16T05:54:07.932665Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT05562830","A Substudy of Investigational Agents in Programmed Cell Death-1\u002FLigand 1 (PD-1\u002FL1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)",[20],"2026-08-26T02:15:17.167444Z","2026-05-13T02:55:06.362668Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06534983","A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)",[27],"2026-08-03T02:29:26.433866Z","2026-05-05T02:43:29.729273Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06682728","Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence",[27],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:29.669697Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT07043972","Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced\u002FMetastatic Urothelial Carcinoma",[27],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.501213Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06184516","Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy",[27],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:29.398889Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07232602","KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D\u002FKEYMAKER-U04)",[20],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:29.339887Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":84,"content_modified":85},"NCT07416123","A Study of GEN1106 in Participants With Solid Tumors",[83],"Phase 1","2026-08-26T02:17:15.156099Z","2026-05-05T02:43:29.324024Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT03945162","Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive\u002FIntolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients",[27],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:29.284935Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT05239624","Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer",[27],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:29.225557Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT07140315","DK222 Study at Hopkins",[83],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:29.220680Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT07106762","Phase 2\u002F3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy",[40],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:29.162482Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT03547973","Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread",[27],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:29.070490Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT04724018","Sacituzumab Govitecan Plus EV in Metastatic UC",[20],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:28.881436Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT07193511","BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)",[20],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:28.855106Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT06439836","Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy",[83],"2026-08-26T02:15:18.897219Z","2026-05-05T02:43:28.815108Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT07218380","A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract",[12],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:28.563241Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT04865939","Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma",[12],"2026-08-26T02:15:51.395565Z","2026-05-05T02:43:28.530287Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT07221942","Pembrolizumab Maintenance After Enfortumab Vedotin (EV)\u002FPembro Induction in Front-Line Metastatic Urothelial Carcinoma",[27],"2026-08-26T02:18:24.494016Z","2026-05-05T02:43:28.518430Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT07183319","Circulating Tumor DNA Response In Urothelial Cancer",[27],"2026-08-26T02:18:49.989941Z","2026-05-05T02:43:28.470064Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT05394337","Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma",[20],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.369435Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT07421700","Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer",[20],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:28.311992Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT04878029","Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer",[83],"2026-08-26T02:16:12.203827Z","2026-05-05T02:43:27.797259Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT05929235","A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma",[83],"2026-08-03T02:31:37.197247Z","2026-05-05T02:43:27.396390Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT05614739","FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3",[83],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:26.956478Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":192,"content_modified":193},"NCT07484022","Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer",[83],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:26.685231Z",{"nct_id":195,"title":196,"phases":197,"status":13,"updated_at":174,"content_modified":198},"NCT04879329","A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2",[27],"2026-05-05T02:43:26.678147Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT06394570","Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer",[20],"2026-08-26T02:16:00.194860Z","2026-05-05T02:35:31.746992Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT07048457","Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma",[27],"2026-08-26T02:19:29.119921Z","2026-04-29T02:57:57.152601Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT06874335","A Phase 1 Study of BHV-1530 in Advanced Solid Tumors",[83],"2026-08-26T02:17:07.954622Z","2026-07-19T19:36:05.062317Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT07532902","A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer",[83],"2026-08-26T02:15:54.846520Z","2026-07-05T05:32:16.689344Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":90,"content_modified":227},"NCT04064359","Safety and Preliminary Efficacy of OBT076 in Recurrent\u002FMetastatic CD205+ Solid Tumors",[83],"2026-05-05T02:43:28.561630Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT05244551","A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors",[83],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:28.531183Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT06644755","First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors",[83],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:27.064259Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":244,"content_modified":245},"NCT06966024","Study of DCC-2812 in Participants With Advanced Genitourinary Cancers",[83],"2026-08-26T02:17:10.213717Z","2026-05-05T02:43:26.722480Z",{"nct_id":247,"title":248,"phases":249,"status":13,"updated_at":250,"content_modified":251},"NCT06101290","Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)",[],"2026-08-26T02:17:21.315591Z","2026-05-05T02:35:31.729627Z",{"nct_id":253,"title":254,"phases":255,"status":13,"updated_at":256,"content_modified":257},"NCT05719558","A Study of ASP1002 in Adults for Treatment of Solid Tumors",[83],"2026-08-26T02:16:05.813655Z","2026-07-24T01:27:14.892649Z",{"nct_id":259,"title":260,"phases":261,"status":13,"updated_at":262,"content_modified":263},"NCT06293898","Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors",[83],"2026-08-26T02:16:23.080181Z","2026-07-24T01:27:14.888332Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":268,"content_modified":269},"NCT06529822","Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease",[83],"2026-08-26T02:15:24.145250Z","2026-07-19T19:36:05.068854Z",{"nct_id":271,"title":272,"phases":273,"status":13,"updated_at":274,"content_modified":275},"NCT07186842","A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9",[20],"2026-08-26T02:15:27.567165Z","2026-07-19T19:36:05.067561Z",{"nct_id":277,"title":278,"phases":279,"status":13,"updated_at":84,"content_modified":280},"NCT04104776","A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas",[20],"2026-07-05T05:32:16.792523Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":41,"content_modified":285},"NCT07287995","A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors",[20],"2026-07-05T05:32:16.680665Z",{"nct_id":287,"title":288,"phases":289,"status":13,"updated_at":290,"content_modified":291},"NCT07277413","A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors",[83],"2026-08-26T02:16:01.910993Z","2026-07-05T05:32:16.679197Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT07354100","Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy",[20],"2026-08-26T02:18:52.966503Z","2026-06-17T02:29:30.060269Z",{"nct_id":299,"title":300,"phases":301,"status":13,"updated_at":302,"content_modified":303},"NCT04895709","A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors",[20],"2026-08-26T02:19:00.742020Z","2026-06-16T05:54:07.907527Z",{"nct_id":305,"title":306,"phases":307,"status":13,"updated_at":308,"content_modified":309},"NCT06330064","A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)",[27],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:29.734746Z",[311,315,319,323,326,329],{"biomarker":312,"count":313,"slug":314},"MSI1 Gene",8,"msi1-gene",{"biomarker":316,"count":317,"slug":318},"Programmed Cell Death 1 Ligand 1",7,"programmed-cell-death-1-ligand-1",{"biomarker":320,"count":321,"slug":322},"ERBB2 Gene",3,"erbb2-gene",{"biomarker":324,"count":321,"slug":325},"Fibroblast Growth Factor Receptor 3","fibroblast-growth-factor-receptor-3",{"biomarker":327,"count":321,"slug":328},"MRC1 wt Allele","mrc1-wt-allele",{"biomarker":330,"count":321,"slug":331},"TPM2 wt Allele","tpm2-wt-allele",[333,337,341,345,349,353,357,361,365,369,373,377,380,384,388,392,395,399,403,407,410,413,416,420],{"state":334,"count":335,"slug":336},"Texas",63,"texas",{"state":338,"count":339,"slug":340},"New York",54,"new-york",{"state":342,"count":343,"slug":344},"California",49,"california",{"state":346,"count":347,"slug":348},"Florida",40,"florida",{"state":350,"count":351,"slug":352},"Tennessee",39,"tennessee",{"state":354,"count":355,"slug":356},"Michigan",33,"michigan",{"state":358,"count":359,"slug":360},"Virginia",32,"virginia",{"state":362,"count":363,"slug":364},"Massachusetts",30,"massachusetts",{"state":366,"count":367,"slug":368},"Illinois",29,"illinois",{"state":370,"count":371,"slug":372},"Ohio",28,"ohio",{"state":374,"count":375,"slug":376},"New Jersey",25,"new-jersey",{"state":378,"count":375,"slug":379},"Pennsylvania","pennsylvania",{"state":381,"count":382,"slug":383},"Colorado",21,"colorado",{"state":385,"count":386,"slug":387},"North Carolina",20,"north-carolina",{"state":389,"count":390,"slug":391},"Maryland",18,"maryland",{"state":393,"count":390,"slug":394},"Washington","washington",{"state":396,"count":397,"slug":398},"Georgia",17,"georgia",{"state":400,"count":401,"slug":402},"Utah",15,"utah",{"state":404,"count":405,"slug":406},"Connecticut",14,"connecticut",{"state":408,"count":405,"slug":409},"Missouri","missouri",{"state":411,"count":405,"slug":412},"South Carolina","south-carolina",{"state":414,"count":405,"slug":415},"Wisconsin","wisconsin",{"state":417,"count":418,"slug":419},"Arizona",13,"arizona",{"state":421,"count":422,"slug":423},"Indiana",11,"indiana"]